- Home
- AIO vs ARDX Comparison
AIO vs ARDX Comparison
Compare AIO & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIO | ARDX |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 927.8M | 996.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AIO | ARDX |
|---|---|---|
| Price | $26.67 | $3.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 71.8K | ★ 4.2M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $20.91 | $3.89 |
| 52 Week High | $28.60 | $8.40 |
Technical Indicators
Market Signals| Indicator | AIO | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 18.58 |
| Support Level | $25.05 | N/A |
| Resistance Level | $26.67 | $6.16 |
| Average True Range (ATR) | 0.51 | 0.18 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 93.17 | 4.07 |
Price Performance
Historical ComparisonAbout AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.